Aim of studies: evaluate the action of complex therapy with rophlumilast on clinical course in the patients with COPD of C, D types during a year.
Dynamics of main clinical data in the groups of patients in 6 months of treatment (M±95%CI) Notes: a symbol * means the diferences between the data in the groups before and after the treatment (*p<0,01, ** -p<0,001 ); symbol # means the diference between the data of the1st and 2nd groups after the treatment (#-p>0,05, ##-p<0,05) .
By the end of observation period (in 12 months) manifestation of all parameters studied in comparison with the initial data decreased veriied (Table 2) .
Along with it, the manifestation of dyspnea (p<0,05), sputum (p<0,05) and cough (p<0,01) were veriied less than in the group treated with standard pharmacological scheme. Frequency of acute attacks of COPD during a year was less in patients of the 2nd group in 1,5 times than in the 1st group (p<0,05). Table 2 Dynamics of main clinical data in the groups of patients in 12 months of treatment (M±95% CI) Notes: symbol * means the diferences before and after the treatment (*-p<0,05, ** -p<0,01;***-p<0,05), symbol # means the diferences between the data of the 1st and 2nd groups after the treatment (# -p<0,05, ## -p< 0,01).
Conclusions The data obtained are in accordance with up-to-date notions that complex therapy of COPD complemented with modern anti-inlammatory preparations is able not only to improve clinical course of COPD, its clinical signs, but decrease signiicantly the frequency of acute attacks of COPD that is the marker of disease severity and enhance the rate of pulmonary function decrease. Thus, our research points out to the essential anti-inlammatory action of rophlumilast and determine reasonable long-term administration of this remedy for the patients with high risk types of COPD. The question of administration of rophlumilast to the patients of lower risk type needs the further investigation. 5.Kulik E.G., Pavlenko V.I., Naryshkina S.V. Тhe dynamics of markers of endothelial dysfunction at application of rolumilast in patients with chronic obstructive pulmonary disease // The 11th Sino-Russia Forum of Biomedical and Pharmaceutical Science The conference proceedings. 2014. P. 16-18.
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